DENVER, April 13, 2016 -- General Cannabis Corporation (OTCQB:CANN) today announced that it has reached agreements with substantially all of the holders of its existing indebtedness to dates beyond January 2017. Subject to certain conditions, the Company expects the restructuring transactions to close by April 30, 2016.
The maturity dates of all indebtedness are expected to be extended to at least January 31, 2017 on substantially the same terms and conditions as the previous debt arrangements. The refinancings are not expected to contain any material changes to existing covenants or other terms of the respective credit facilities, beyond those described above. In connection with the refinancings, the Company will issue warrants to purchase its common stock at $1.07 per share. The warrants will have a one-year term. General Cannabis anticipates issuing a total of approximately 750,000 warrants in connection with the refinancings. The Company anticipates certain fees and noncash expenses associated with the transaction, but does not expect to incur any prepayment premiums as a result of the refinancing.
“We appreciate our lenders’ confidence in General Cannabis and in our ability to continue to execute our business plan. These modifications extend all maturities until at least 2017 allowing management to focus on current operational objectives,” said Robert Frichtel, Chief Executive Officer. "These transactions are an important part of the financial management component of our business plan,” continued Frichtel. "The extensions provides us with time and additional flexibility to pursue organic growth opportunities and shareholder-enhancing initiatives."
“Having built the premier platform in the cannabis industry, we are now focusing on future expansion and acquisitions. These refinancings give us the flexibility to pursue numerous strategic opportunities,” noted Executive Chairman Michael Feinsod. He continued, “We are excited about the future for General Cannabis.”
The Company internally managed the restructuring negotiations. General Cannabis was advised by Sichenzia Ross Friedman Ference LLP in the refinancing process.
About
General Cannabis Corporation is the all-in-one resource for the highest quality service providers available to the regulated Cannabis Industry. We are a trusted partner to the cultivation, production and retail side of the cannabis business. We do this through a combination of strong operating divisions such as real estate, consulting, security, financing and the distribution of important infrastructure products to grow facilities and dispensaries. As a synergistic holding company, our subsidiaries are able to leverage the strengths of each other, as well as a larger balance sheet, to succeed.
Safe Harbor
This presentation contains forward-looking statements which relate to future events or General Cannabis’ future performance or financial condition. Any statements that are not statements of historical fact (including statements containing the words “believes,” “should,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements. These forward-looking statements are not guarantees of future performance, condition or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward looking statements as result of a number of factors, including those described from time to time in General Cannabis’ filings with the Securities and Exchange Commission. General Cannabis undertakes no duty to update any forward-looking statements made herein.
Contact Robert Frichtel CEO – General Cannabis Corp (303) 759-1300


Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 



